Physician profile
Poonam Singh
NPI 1457346496
$443.23
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $15.01 · 2021: $31.53 · 2022: $20.91 · 2023: $16.57 · 2024: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $144.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $107.01 | 2021-2024 | Minimed 780g |
| Medtronic Minimed, INC. | $45.92 | 2019 | |
| Novo Nordisk INC | $40.34 | 2019-2021 | |
| Valeritas, INC. | $33.10 | 2019 | |
| Glaxosmithkline, LLC. | $28.40 | 2019-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $27.09 | 2019 | |
| Astellas Pharma US INC | $21.20 | 2024 | Veozah |
| Abbott Laboratories | $20.91 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.46 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.08 | 2019 | |
| Lilly USA, LLC | $16.57 | 2023 | Mounjaro |
| Amgen INC. | $16.56 | 2019 | |
| Mylan Specialty L.P. | $16.34 | 2019 | |
| Pfizer INC. | $16.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Poonam Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.